MA52942A - Composés inhibiteurs d'oga - Google Patents
Composés inhibiteurs d'ogaInfo
- Publication number
- MA52942A MA52942A MA052942A MA52942A MA52942A MA 52942 A MA52942 A MA 52942A MA 052942 A MA052942 A MA 052942A MA 52942 A MA52942 A MA 52942A MA 52942 A MA52942 A MA 52942A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- inhibitor
- Prior art date
Links
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382456 | 2018-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52942A true MA52942A (fr) | 2021-04-28 |
Family
ID=62784079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052942A MA52942A (fr) | 2018-06-21 | 2019-06-20 | Composés inhibiteurs d'oga |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210277003A1 (fr) |
| EP (1) | EP3810586A1 (fr) |
| JP (1) | JP2021528404A (fr) |
| CN (1) | CN112313212B (fr) |
| AU (1) | AU2019291101A1 (fr) |
| CA (1) | CA3103049A1 (fr) |
| MA (1) | MA52942A (fr) |
| WO (1) | WO2019243535A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3048217A1 (fr) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| ES2905676T3 (es) | 2017-05-22 | 2022-04-11 | Amgen Inc | Inhibidores de KRAS G12C y métodos para su uso |
| CN111051306B (zh) | 2017-09-08 | 2023-01-03 | 美国安进公司 | Kras g12c的抑制剂及其使用方法 |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| ES2995514T3 (en) | 2018-05-04 | 2025-02-10 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| AU2019278998B2 (en) | 2018-06-01 | 2023-11-09 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| CA3100390A1 (fr) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Inhibiteurs de kras g12c regroupant un cycle de piperazine et utilisation dans le traitement du cancer |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
| CA3117222A1 (fr) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
| CN114144414B (zh) | 2019-05-21 | 2025-11-07 | 美国安进公司 | 固态形式 |
| TW202132271A (zh) * | 2019-11-14 | 2021-09-01 | 美商安進公司 | Kras g12c抑制劑化合物之改善的合成 |
| IL314883A (en) | 2022-03-07 | 2024-10-01 | Amgen Inc | Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| CN114573467B (zh) * | 2022-03-21 | 2023-11-21 | 北京印刷学院 | 2,4-二甲基-3-氨基苯甲酸的合成工艺 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017003658B1 (pt) * | 2014-08-28 | 2022-12-06 | Asceneuron Sa | Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica |
| US10913733B2 (en) * | 2015-12-18 | 2021-02-09 | Alectos Therapeutics Inc. | Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof |
| EP3419976B1 (fr) * | 2016-02-25 | 2021-04-07 | Asceneuron SA | Sels d'addition d'acide de dérivés de pipérazine |
| US11612599B2 (en) * | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
-
2019
- 2019-06-20 US US17/253,505 patent/US20210277003A1/en not_active Abandoned
- 2019-06-20 JP JP2020570424A patent/JP2021528404A/ja not_active Withdrawn
- 2019-06-20 CN CN201980041118.XA patent/CN112313212B/zh not_active Expired - Fee Related
- 2019-06-20 WO PCT/EP2019/066394 patent/WO2019243535A1/fr not_active Ceased
- 2019-06-20 AU AU2019291101A patent/AU2019291101A1/en not_active Abandoned
- 2019-06-20 MA MA052942A patent/MA52942A/fr unknown
- 2019-06-20 EP EP19733712.4A patent/EP3810586A1/fr not_active Withdrawn
- 2019-06-20 CA CA3103049A patent/CA3103049A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021528404A (ja) | 2021-10-21 |
| CN112313212A (zh) | 2021-02-02 |
| WO2019243535A1 (fr) | 2019-12-26 |
| US20210277003A1 (en) | 2021-09-09 |
| EP3810586A1 (fr) | 2021-04-28 |
| CN112313212B (zh) | 2023-05-05 |
| CA3103049A1 (fr) | 2019-12-26 |
| AU2019291101A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| IL292753A (en) | Compounds | |
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| EP3941898C0 (fr) | Composés fongicides | |
| MA52948A (fr) | Composés | |
| IL286833A (en) | Compositions containing brazzein | |
| EP3740487A4 (fr) | Composés benzamide | |
| MA51669A (fr) | Composés | |
| DK4083038T3 (da) | Pyridazinylthiazolcarboxamidforbindelse | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| EP3464275A4 (fr) | Composés inhibiteurs de l'egfr | |
| MA53003A (fr) | Composés | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA52946A (fr) | Composés | |
| EP3808747A4 (fr) | Composé d'imidazopyridinone | |
| EP4077318A4 (fr) | Composés | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| EP3833342A4 (fr) | Composés d'imidazotétrazine | |
| LT3867247T (lt) | Naujieji junginiai | |
| EP4003986A4 (fr) | Composés inhibiteurs |